Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 4/20 | 0.44 |
| ▸ | CNR2 | P34972 | 7/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 3/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.39 |
| ▸ | ULK1 | O75385 | 1/20 | 0.39 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 4/20 | 0.39 |
| ▸ | CNR1 | P21554 | 4/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL945213 | 1.00 | PIM1 (0.44) | PIM1CNR2EPHX2FLT3KIT | |
| SCHEMBL945211 | 1.00 | PIM1 (0.44) | PIM1CNR2EPHX2FLT3KIT | |
| SCHEMBL12917304 | 0.89 | PIM1 (0.43) | PIM1CNR2EPHX2FLT3ULK1 | |
| SCHEMBL12917306 | 0.89 | PIM1 (0.43) | PIM1CNR2EPHX2FLT3ULK1 | |
| SCHEMBL15353733 | 0.89 | PIM1 (0.43) | PIM1CNR2EPHX2FLT3ULK1 | |
| SCHEMBL12916454 | 0.88 | ULK1 (0.48) | PIM1CNR2FLT3KITULK1 | |
| SCHEMBL27796249 | 0.86 | CNR2 (0.46) | CNR2EPHX2ULK1ULK2AR | |
| SCHEMBL27796248 | 0.86 | CNR2 (0.46) | CNR2EPHX2ULK1ULK2AR | |
| SCHEMBL12916452 | 0.85 | PIM1 (0.46) | PIM1EPHX2FLT3PIM2KCNH2 | |
| SCHEMBL15850035 | 0.83 | CNR2 (0.49) | PIM1CNR2EPHX2ULK1ULK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234973-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-07-02 | — | — | EP | disclosed |
| EP-2234973-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-07-02 | — | — | EP | disclosed |
| US-8569495-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-10-29 | — | — | US | disclosed |
| US-8569495-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-10-29 | — | — | US | disclosed |
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-01-27 | — | — | US | disclosed |
| EP-2234973-A1 | ANTHELMINTIC AGENTS AND THEIR USE | Intervet International B.V. (NL) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009077527-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | PIM1 3270/4885CNR2 1257/4885EPHX2 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.